Skip to main content

Advertisement

Figure 2 | Cell & Bioscience

Figure 2

From: Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bearing human gastric cancer

Figure 2

ACBP-L and low dose Cisplatin combined treatment suppresses gastric tumor growth in the xenograft tumor model. ACBP-L suppresses tumor growth in vivo. The in vivo tumor growth experiment was established by subcutaneous injection of 2×107 MGC-803 gastric cancer cells. After tumors were palpable and when the sizes of tumors were about ~10 mm3, the tumor bearing mice were randomized with eight mice (n = 8) each into four groups: control with daily intraperitoneal injection of saline, daily injection of ACBP-L (7 μg/mouse) alone, Cisplatin alone (5 mg/kg every five days for 4 times, given the drug at day 6, 11, 16, 21), and Cisplatin (5 mg/kg, twice giving at day 6 and 16) plus daily ACBP-L. The tumor volumes were measured every three days (a). The final tumor volumes were calculated before the end of experiments (b). The data were calculated and presented as mean ± standard deviation (SD). Statistical significance was determined by Student t-test (statistical difference was indicated as p < 0.05, when compared with the control group (*), or compared with ACBP-L treated alone group (#). (c and d) Tumor weight was measured after harvest, and the data were calculated and presented as mean ± standard deviation (SD). Statistical significance (p < 0.05) was determined by Student t-test when compared with the control (*) and ACBP-L treated alone group (#).

Back to article page